Last reviewed · How we verify
mFOLFOXIRI adjuvant chemotherapy
mFOLFOXIRI is a combination chemotherapy regimen that targets rapidly dividing cancer cells.
mFOLFOXIRI is a combination chemotherapy regimen that targets rapidly dividing cancer cells. Used for Adjuvant treatment of stage III colon cancer.
At a glance
| Generic name | mFOLFOXIRI adjuvant chemotherapy |
|---|---|
| Also known as | Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil |
| Sponsor | Sun Yat-sen University |
| Drug class | Platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It combines oxaliplatin, 5-fluorouracil, and irinotecan to inhibit DNA replication and induce apoptosis in cancer cells. This regimen is used in the treatment of colorectal cancer.
Approved indications
- Adjuvant treatment of stage III colon cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
- Neutropenia
- Anemia
Key clinical trials
- mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer (PHASE3)
- Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD) (PHASE3)
- mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer (PHASE2)
- Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mFOLFOXIRI adjuvant chemotherapy CI brief — competitive landscape report
- mFOLFOXIRI adjuvant chemotherapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI